Management of Pseudogout in Older Adults

Acute Attack Management

• The European League Against Rheumatism (EULAR) guidelines recommend intra-articular glucocorticosteroid injection combined with joint aspiration as the optimal first-line treatment for acute pseudogout in older adults, followed by a short course of oral prednisone 0.5 mg/kg/day for 5-10 days if systemic therapy is needed 1, 2
• Joint aspiration should be performed first to confirm CPP crystals under polarized light microscopy and exclude septic arthritis, as injecting steroids into an infected joint can be catastrophic 1
• Intra-articular injection of triamcinolone acetonide 60 mg (or equivalent long-acting corticosteroid) directly into the affected joint after aspiration provides rapid symptom relief with minimal systemic effects 1, 2
• The approach of intra-articular injection has the highest strength of evidence from EULAR guidelines 1
• Ice application and temporary rest of the joint can be combined with intra-articular injection for additional relief 3

Systemic Steroid Treatment

• Oral prednisone/prednisolone 0.5 mg/kg/day for 5-10 days, then discontinue without tapering if course is short, is recommended as a second-line treatment when intra-articular injection is not feasible 2
• Alternative regimens include full dose for 2-5 days, then taper over 7-10 days 2
• Intramuscular triamcinolone acetonide 60 mg as a single dose showed ≥50% clinical improvement in all patients within 14 days 2

Alternative Acute Treatments

• The American College of Rheumatology recommends using NSAIDs with extreme caution in older adults due to cardiovascular, renal, and gastrointestinal risks 3
• Always assess cardiovascular, renal, and metabolic comorbidities before prescribing NSAIDs in patients over 60 1
• Evidence for NSAID use is extrapolated from gout studies, not specific CPPD trials 3
• Colchicine is less effective for acute attacks than steroids but can be considered, with a risk of diarrhea and drug interactions in elderly patients with polypharmacy 4

Chronic CPPD Management

• Low-dose colchicine 0.5 mg twice daily has an NNT of 2 for >30% pain reduction in chronic CPPD with knee OA, as demonstrated in a double-blind RCT with minimal side effects 4, 1
• Hydroxychloroquine showed NNT of 2 for clinical response (>30% reduction in swollen/tender joint count) in a 6-month RCT 4, 5
• Low-dose methotrexate 5-10 mg weekly showed excellent response in refractory cases with marked improvement within 7.4 weeks, though evidence is limited to small case series 4, 5

Screening for Metabolic Comorbidities

• Screen all patients with early-onset CPPD (age <60) or severe disease for primary hyperparathyroidism (OR 3.03 for CPPD association), hemochromatosis, hypomagnesemia, and hypophosphatasia 5
• Treat identified metabolic conditions per their respective guidelines, though whether this affects CPPD outcomes remains unclear 5

Key Distinctions and Precautions

• Avoid high molecular weight hyaluronan intra-articular injections, as they may induce acute CPPD attacks 1
• Do not treat asymptomatic chondrocalcinosis, as it is age-related and requires no intervention 3
• Never assume infection is excluded without joint aspiration in monoarticular presentations before steroid injection 2
• Unlike gout, there is currently no treatment to dissolve or prevent CPP crystal formation, and all therapy is directed at controlling inflammation and symptoms 3, 5

Treatment of Pseudogout

Pharmacological Management

• The European League Against Rheumatism (EULAR) guidelines support the use of anakinra (IL-1 receptor antagonist) for resolution of signs and symptoms within 2 weeks in resistant pseudogout cases, when conventional therapies are ineffective, poorly tolerated, or contraindicated 6
• Meniscal calcifications (chondrocalcinosis) on imaging are characteristic of pseudogout, not gout, according to the American College of Radiology 7

Diagnostic Considerations

• No treatment is currently available to dissolve or prevent CPP crystal formation, and all therapy is directed at controlling inflammation and symptoms, as stated by the American College of Rheumatology 7

Evidence‑Based Recommendations for Pseudogout (CPPD) Management

Acute Attack Management

• Intra‑articular triamcinolone (≈60 mg) injected immediately after joint aspiration provides rapid symptom relief in acute mono‑ or oligo‑articular pseudogout attacks. (Annals of the Rheumatic Diseases, 2011) 8
• Adjunctive ice application and brief joint rest after aspiration and steroid injection further improve symptom control. (Annals of the Rheumatic Diseases, 2011) 9

Systemic Therapy When Intra‑articular Injection Is Not Feasible

• A single intramuscular dose of triamcinolone acetonide (≈60 mg) yields ≥50 % clinical improvement in all patients within 14 days. (Annals of the Rheumatic Diseases, 2011) 8
• Parenteral ACTH (40–80 U three times) resolves acute attacks in a mean of 4.2 days; mild hypokalaemia and hyperglycaemia may occur. (Annals of the Rheumatic Diseases, 2011) 8

NSAIDs and Colchicine: Safety Considerations

• Evidence for NSAID efficacy in pseudogout is extrapolated from gout studies; no CPPD‑specific trials exist. (Annals of the Rheumatic Diseases, 2011) 9
• When colchicine is used for an acute attack, a low dose of 0.5 mg three to four times daily is recommended to minimise diarrhoea and drug‑interaction risk. (Annals of the Rheumatic Diseases, 2011) 9

Prophylaxis for Recurrent Attacks

• Low‑dose colchicine (0.5 mg twice daily) reduces the frequency of recurrent attacks in uncontrolled studies. (Annals of the Rheumatic Diseases, 2011) 8
• Prophylaxis is advised only for patients with documented recurrent attacks; it is not indicated for asymptomatic chondrocalcinosis. (Annals of the Rheumatic Diseases, 2011) [9][8]

Chronic CPPD Management

• Low‑dose oral corticosteroids may be employed when first‑line agents fail. (Annals of the Rheumatic Diseases, 2011) 8

CPPD Co‑existing with Osteoarthritis

• Management follows standard osteoarthritis guidelines, adding low‑dose colchicine to address the inflammatory component. (Annals of the Rheumatic Diseases, 2011) 8

Screening for Metabolic Associations

• Patients with early‑onset or severe CPPD should be screened for primary hyperparathyroidism, haemochromatosis, hypomagnesemia, and hypophosphatasia; identified conditions are treated according to their respective specialty guidelines. (Annals of the Rheumatic Diseases, 2011) 8

Critical Pitfalls

• Do not treat asymptomatic chondrocalcinosis; it represents an age‑related finding without need for intervention. (Annals of the Rheumatic Diseases, 2011) [9][8]